Sensus Healthcare Inc (SRTS) — Titan Protect Analysis

SRTS

Sensus Healthcare Inc

Healthcare · ·

$2.70

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$46M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-168.57

Based on estimated future earnings — lower means cheaper

Rev Growth

-62.2%

Year-over-year revenue change

Profit Margin

-28.1%

How much profit the company keeps from each dollar of revenue

ROE

-14.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$6.00

+122% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Sensus Healthcare Inc

Sensus Healthcare, Inc. operates as a medical device company that manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as oth

https://sensushealthcare.com

Country: United States Employees: 60 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.118

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0438

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.438

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-30.1%

Historical annualised return based on price data

Max Drawdown

-68.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.19

Moves slightly more than the broader market

52W High

$5.92

54% below the year high

52W Low

$2.66

2% above the year low

Avg Volume

62,693

Average daily shares traded — higher means easier to buy and sell

Short Ratio

11.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.47

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.98

Moderate leverage — manageable

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

43.2%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-63.7%

Profit from core operations before interest and tax

Free Cash Flow

$4M

Positive — the business generates more cash than it spends

Revenue (TTM)

$27M

Total revenue over the last 12 months

Net Income

$-7,719,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$6.50

Target Median

$6.00

Target Low

$4.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go